Stories
Rubicon Research Receives One US FDA Form 483 Observation for Satara Plant
C
CNBC TV18•09-10-2026, 22:40
Rubicon Research Receives One US FDA Form 483 Observation for Satara Plant
- •Rubicon Research Ltd announced that the US FDA issued one observation in Form 483 following an unannounced inspection of its Satara manufacturing facility in Maharashtra.
- •The pharmaceutical company clarified that the observation is procedural and unrelated to data integrity, expressing confidence in resolving it swiftly.
- •This marks the company's third successful unannounced US FDA inspection in the financial year 2026-27, following reviews of facilities in Toronto and Pithampur.
Key Questions Answered
The United States Food and Drug Administration issued one observation in Form 483 following an unannounced inspection of Rubicon Research's manufacturing facility in Satara, Maharashtra, conducted from October 5 to October 9, 2026.
A Form 483 is a list of observations issued by US FDA inspectors after an inspection concludes, though it does not represent a final determination regarding GMP compliance. Once issued, the company is given 15 days to submit a response outlining steps to resolve the observations.
The Satara manufacturing facility's previous US FDA inspection took place in January 2023 with prior intimation provided to the company.
